Zokinvy approved to treat ultra-rare paediatric diseases in Japan
Zokinvy is indicated for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL), two ultra-rare paediatric diseases…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Jan 24
Zokinvy is indicated for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL), two ultra-rare paediatric diseases…
19 Jan 24
Lipocine retains all rights for territories outside the United States and Canada, and all non-TRT rights globally
19 Jan 24
Study demonstrated the DMT’s effectiveness as a melanoma rule-out test for all skin types
19 Jan 24
The Novo Nordisk Foundation is committing up to USD 25 million to support the early-stage development of innovative tools to prevent,…
18 Jan 24
Upon completion of the merger, expected to be completed in the first half of this year, Taro will…
18 Jan 24
In conjunction with the acquisition of PPS, Alcami is enhancing its presence in central North Carolina's pharmaceutical storage…
18 Jan 24
The Gibco CTS Cellmation Software is designed to connect and integrate workflows across several Thermo Fisher Scientific cell…
18 Jan 24
Xenetic has signed the research funding agreement and material transfer agreement with UVA to obtain an exclusive license…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
18 Jan 24
Along with istaroxime, the agreement licences Windtree’s preclinical next-generation SERCA2a activators, called dual mechanism SERCA2a activators
18 Jan 24
The US FDA has cleared Amplia's Investigational New Drug (IND) Application for a clinical trial of narmafotinib in…